Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature - PubMed (original) (raw)

Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

Digant Gupta et al. J Ovarian Res. 2009.

Abstract

CA125 is the gold standard tumor marker in ovarian cancer. Serum level of CA125 is used to monitor response to chemotherapy, relapse, and disease progression in ovarian cancer patients. Thus, it is reasonable to investigate whether CA125 may have utility as a prognostic indicator as well in ovarian cancer. A large number of epidemiological studies have been carried out to this effect. This review summarizes all available epidemiological literature on the association between CA125 levels and survival in ovarian cancer. To place these studies in context, we provide some background information on CA125 and its role in ovarian cancer.

PubMed Disclaimer

Similar articles

• Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
  Lee M, Chang MY, Yoo H, Lee KE, Chay DB, Cho H, Kim S, Kim YT, Kim JH. Lee M, et al. Yonsei Med J. 2016 May;57(3):580-7. doi: 10.3349/ymj.2016.57.3.580. Yonsei Med J. 2016. PMID: 26996555 Free PMC article.
• Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
  Abu Hassaan SO. Abu Hassaan SO. Dan Med J. 2018 Apr;65(4):B5463. Dan Med J. 2018. PMID: 29619933 Review.
• Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
  Kang WD, Choi HS, Kim SM. Kang WD, et al. Gynecol Oncol. 2010 Jan;116(1):57-60. doi: 10.1016/j.ygyno.2009.09.019. Epub 2009 Oct 9. Gynecol Oncol. 2010. PMID: 19818996
• Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study.
  Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, Parma G, Cristofani R. Gadducci A, et al. Int J Gynecol Cancer. 1997 Jan;7(1):78-83. doi: 10.1046/j.1525-1438.1997.00424.x. Int J Gynecol Cancer. 1997. PMID: 12795808
• New tumor markers: CA125 and beyond.
  Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. Bast RC Jr, et al. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x. Int J Gynecol Cancer. 2005. PMID: 16343244 Review.

Cited by

• Recreational physical activity and survival in African-American women with ovarian cancer.
  Abbott SE, Camacho F, Peres LC, Alberg AJ, Bandera EV, Bondy M, Cote ML, Funkhouser E, Moorman PG, Peters ES, Qin B, Schwartz AG, Barnholtz-Sloan J, Terry P, Schildkraut JM. Abbott SE, et al. Cancer Causes Control. 2018 Jan;29(1):77-86. doi: 10.1007/s10552-017-0986-8. Epub 2017 Nov 29. Cancer Causes Control. 2018. PMID: 29188593 Free PMC article.
• Exosome RNA Sequencing as a Tool in the Search for Cancer Biomarkers.
  Elkommos-Zakhary M, Rajesh N, Beljanski V. Elkommos-Zakhary M, et al. Noncoding RNA. 2022 Nov 9;8(6):75. doi: 10.3390/ncrna8060075. Noncoding RNA. 2022. PMID: 36412910 Free PMC article. Review.
• Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods.
  Al-Ogaidi I, Aguilar ZP, Suri S, Gou H, Wu N. Al-Ogaidi I, et al. Analyst. 2013 Oct 7;138(19):5647-53. doi: 10.1039/c3an00668a. Analyst. 2013. PMID: 23917224 Free PMC article.
• Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
  Hu X, Zhang J, Cao Y. Hu X, et al. BMC Cancer. 2022 May 14;22(1):544. doi: 10.1186/s12885-022-09637-7. BMC Cancer. 2022. PMID: 35568827 Free PMC article.
• A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
  Mysona D, Pyrzak A, Purohit S, Zhi W, Sharma A, Tran L, Tran P, Bai S, Rungruang B, Ghamande S, She JX. Mysona D, et al. Gynecol Oncol. 2019 Mar;152(3):574-580. doi: 10.1016/j.ygyno.2018.12.015. Epub 2018 Dec 18. Gynecol Oncol. 2019. PMID: 30578005 Free PMC article.

References

1. 1. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521–528. - PubMed
2. 1. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol. 1994;84:760–764. - PubMed
3. 1. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97:519–523. doi: 10.1016/j.ygyno.2005.02.007. - DOI - PubMed
4. 1. Hannibal CG, Cortes R, Engholm G, Kjaer SK. Survival of ovarian cancer patients in Denmark: Excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta Obstet Gynecol Scand. 2008. pp. 1–9. - PubMed
5. 1. van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444–450. doi: 10.1006/gyno.2000.5982. - DOI - PubMed

LinkOut - more resources

• Full Text Sources

  • BioMed Central
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal